Copyright Reports & Markets. All rights reserved.

Global Conjugate Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Conjugate Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Hib Vaccine
    • 1.3.3 Meningococcal Vaccine
    • 1.3.4 Pneumococcal Vaccine
    • 1.3.5 Others
  • 1.4 Market Analysis by End Users
    • 1.4.1 Overview: Global Conjugate Vaccine Consumption Value by End Users: 2021 Versus 2025 Versus 2032
    • 1.4.2 Children
    • 1.4.3 Adult
  • 1.5 Global Conjugate Vaccine Market Size & Forecast
    • 1.5.1 Global Conjugate Vaccine Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Conjugate Vaccine Sales Quantity (2021-2032)
    • 1.5.3 Global Conjugate Vaccine Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Pfizer
    • 2.1.1 Pfizer Details
    • 2.1.2 Pfizer Major Business
    • 2.1.3 Pfizer Conjugate Vaccine Product and Services
    • 2.1.4 Pfizer Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Pfizer Recent Developments/Updates
  • 2.2 GSK
    • 2.2.1 GSK Details
    • 2.2.2 GSK Major Business
    • 2.2.3 GSK Conjugate Vaccine Product and Services
    • 2.2.4 GSK Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 GSK Recent Developments/Updates
  • 2.3 Sanofi
    • 2.3.1 Sanofi Details
    • 2.3.2 Sanofi Major Business
    • 2.3.3 Sanofi Conjugate Vaccine Product and Services
    • 2.3.4 Sanofi Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Sanofi Recent Developments/Updates
  • 2.4 Merck
    • 2.4.1 Merck Details
    • 2.4.2 Merck Major Business
    • 2.4.3 Merck Conjugate Vaccine Product and Services
    • 2.4.4 Merck Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Merck Recent Developments/Updates
  • 2.5 Walvax Biotechnology
    • 2.5.1 Walvax Biotechnology Details
    • 2.5.2 Walvax Biotechnology Major Business
    • 2.5.3 Walvax Biotechnology Conjugate Vaccine Product and Services
    • 2.5.4 Walvax Biotechnology Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Walvax Biotechnology Recent Developments/Updates
  • 2.6 Royal (Wuxi) Bio-Pharmaceutical
    • 2.6.1 Royal (Wuxi) Bio-Pharmaceutical Details
    • 2.6.2 Royal (Wuxi) Bio-Pharmaceutical Major Business
    • 2.6.3 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product and Services
    • 2.6.4 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments/Updates
  • 2.7 Bharat Biotech
    • 2.7.1 Bharat Biotech Details
    • 2.7.2 Bharat Biotech Major Business
    • 2.7.3 Bharat Biotech Conjugate Vaccine Product and Services
    • 2.7.4 Bharat Biotech Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Bharat Biotech Recent Developments/Updates
  • 2.8 Zhifei Biologic
    • 2.8.1 Zhifei Biologic Details
    • 2.8.2 Zhifei Biologic Major Business
    • 2.8.3 Zhifei Biologic Conjugate Vaccine Product and Services
    • 2.8.4 Zhifei Biologic Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Zhifei Biologic Recent Developments/Updates
  • 2.9 Beijing Minhai Biotechnology
    • 2.9.1 Beijing Minhai Biotechnology Details
    • 2.9.2 Beijing Minhai Biotechnology Major Business
    • 2.9.3 Beijing Minhai Biotechnology Conjugate Vaccine Product and Services
    • 2.9.4 Beijing Minhai Biotechnology Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Beijing Minhai Biotechnology Recent Developments/Updates
  • 2.10 SinoPharma
    • 2.10.1 SinoPharma Details
    • 2.10.2 SinoPharma Major Business
    • 2.10.3 SinoPharma Conjugate Vaccine Product and Services
    • 2.10.4 SinoPharma Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 SinoPharma Recent Developments/Updates

3 Competitive Environment: Conjugate Vaccine by Manufacturer

  • 3.1 Global Conjugate Vaccine Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Conjugate Vaccine Revenue by Manufacturer (2021-2026)
  • 3.3 Global Conjugate Vaccine Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Conjugate Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Conjugate Vaccine Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Conjugate Vaccine Manufacturer Market Share in 2025
  • 3.5 Conjugate Vaccine Market: Overall Company Footprint Analysis
    • 3.5.1 Conjugate Vaccine Market: Region Footprint
    • 3.5.2 Conjugate Vaccine Market: Company Product Type Footprint
    • 3.5.3 Conjugate Vaccine Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Conjugate Vaccine Market Size by Region
    • 4.1.1 Global Conjugate Vaccine Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Conjugate Vaccine Consumption Value by Region (2021-2032)
    • 4.1.3 Global Conjugate Vaccine Average Price by Region (2021-2032)
  • 4.2 North America Conjugate Vaccine Consumption Value (2021-2032)
  • 4.3 Europe Conjugate Vaccine Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Conjugate Vaccine Consumption Value (2021-2032)
  • 4.5 South America Conjugate Vaccine Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Conjugate Vaccine Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Conjugate Vaccine Sales Quantity by Type (2021-2032)
  • 5.2 Global Conjugate Vaccine Consumption Value by Type (2021-2032)
  • 5.3 Global Conjugate Vaccine Average Price by Type (2021-2032)

6 Market Segment by End Users

  • 6.1 Global Conjugate Vaccine Sales Quantity by End Users (2021-2032)
  • 6.2 Global Conjugate Vaccine Consumption Value by End Users (2021-2032)
  • 6.3 Global Conjugate Vaccine Average Price by End Users (2021-2032)

7 North America

  • 7.1 North America Conjugate Vaccine Sales Quantity by Type (2021-2032)
  • 7.2 North America Conjugate Vaccine Sales Quantity by End Users (2021-2032)
  • 7.3 North America Conjugate Vaccine Market Size by Country
    • 7.3.1 North America Conjugate Vaccine Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Conjugate Vaccine Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Conjugate Vaccine Sales Quantity by Type (2021-2032)
  • 8.2 Europe Conjugate Vaccine Sales Quantity by End Users (2021-2032)
  • 8.3 Europe Conjugate Vaccine Market Size by Country
    • 8.3.1 Europe Conjugate Vaccine Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Conjugate Vaccine Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Conjugate Vaccine Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Conjugate Vaccine Sales Quantity by End Users (2021-2032)
  • 9.3 Asia-Pacific Conjugate Vaccine Market Size by Region
    • 9.3.1 Asia-Pacific Conjugate Vaccine Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Conjugate Vaccine Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Conjugate Vaccine Sales Quantity by Type (2021-2032)
  • 10.2 South America Conjugate Vaccine Sales Quantity by End Users (2021-2032)
  • 10.3 South America Conjugate Vaccine Market Size by Country
    • 10.3.1 South America Conjugate Vaccine Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Conjugate Vaccine Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Conjugate Vaccine Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Conjugate Vaccine Sales Quantity by End Users (2021-2032)
  • 11.3 Middle East & Africa Conjugate Vaccine Market Size by Country
    • 11.3.1 Middle East & Africa Conjugate Vaccine Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Conjugate Vaccine Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Conjugate Vaccine Market Drivers
  • 12.2 Conjugate Vaccine Market Restraints
  • 12.3 Conjugate Vaccine Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Conjugate Vaccine and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Conjugate Vaccine
  • 13.3 Conjugate Vaccine Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Conjugate Vaccine Typical Distributors
  • 14.3 Conjugate Vaccine Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Conjugate Vaccine market size was valued at US$ 11260 million in 2025 and is forecast to a readjusted size of US$ 13940 million by 2032 with a CAGR of 3.1% during review period.
    Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
    The conjugate vaccine market is experiencing significant growth, primarily driven by the increasing global focus on preventing infectious diseases, especially among infants, children, and the elderly. Conjugate vaccines, which link a weak antigen to a strong carrier protein to enhance immune response, have proven highly effective against diseases like Haemophilus influenzae type b (Hib), pneumococcal, and meningococcal infections. Government immunization programs and public health initiatives—particularly in emerging economies—are expanding vaccine coverage, thereby fueling market demand. Additionally, rising investments from global health organizations (such as GAVI, WHO, and UNICEF), along with growing awareness of the importance of early immunization, are further boosting uptake. Technological advancements in vaccine development, including improved conjugation methods and novel carrier proteins, are enabling the production of more effective and broad-spectrum vaccines, supporting innovation and market expansion.
    However, the conjugate vaccine market also faces notable challenges. High development and production costs, particularly for multivalent vaccines, can limit affordability and access in low-income regions. Stringent regulatory requirements and lengthy clinical trial timelines can delay product approvals, creating barriers for new entrants and smaller biotech firms. Cold chain logistics and storage requirements pose additional challenges in remote or underdeveloped areas, potentially impacting vaccine distribution and efficacy. Vaccine hesitancy, fueled by misinformation and lack of public trust in immunization programs, also poses a growing risk to market growth. Moreover, competition from alternative vaccine technologies, such as mRNA or protein subunit vaccines, may shift focus away from conjugate platforms in the long term. Addressing these challenges will require international collaboration to improve supply chains, expand funding for research and public health infrastructure, and enhance community education on vaccine safety and effectiveness.
    This report is a detailed and comprehensive analysis for global Conjugate Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by End Users. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Conjugate Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (Million Unit), and average selling prices (USD/Unit), 2021-2032
    Global Conjugate Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Million Unit), and average selling prices (USD/Unit), 2021-2032
    Global Conjugate Vaccine market size and forecasts, by Type and by End Users, in consumption value ($ Million), sales quantity (Million Unit), and average selling prices (USD/Unit), 2021-2032
    Global Conjugate Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (Million Unit), and ASP (USD/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Conjugate Vaccine
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Conjugate Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, GSK, Sanofi, Merck, Walvax Biotechnology, Royal (Wuxi) Bio-Pharmaceutical, Bharat Biotech, Zhifei Biologic, Beijing Minhai Biotechnology, SinoPharma, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Conjugate Vaccine market is split by Type and by End Users. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by End Users in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Hib Vaccine
    Meningococcal Vaccine
    Pneumococcal Vaccine
    Others
    Market segment by End Users
    Children
    Adult
    Major players covered
    Pfizer
    GSK
    Sanofi
    Merck
    Walvax Biotechnology
    Royal (Wuxi) Bio-Pharmaceutical
    Bharat Biotech
    Zhifei Biologic
    Beijing Minhai Biotechnology
    SinoPharma
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Conjugate Vaccine product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Conjugate Vaccine, with price, sales quantity, revenue, and global market share of Conjugate Vaccine from 2021 to 2026.
    Chapter 3, the Conjugate Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Conjugate Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by End Users, with sales market share and growth rate by Type, by End Users, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Conjugate Vaccine market forecast, by regions, by Type, and by End Users, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Conjugate Vaccine.
    Chapter 14 and 15, to describe Conjugate Vaccine sales channel, distributors, customers, research findings and conclusion.

    Buy now